Amy B. Middleman, MD, MSEd, MPH
, an Infectious Diseases in Children
Editorial Board member, and colleagues evaluated 420 adolescents aged 16 to 19 years who received a recombinant hepatitis B virus
three-dose series to determine protective titers of antibody to
hepatitis B surface antigen (HBsAg) before and after a challenge dose of
the vaccine. Participants were divided in to two groups, those who had
the series initiation within 7 days of birth (group 1) or at 4 weeks or
more following birth (group 2).